Psorospermin structural requirements for P-glycoprotein resistance reversal

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3617-3623

  Carey, Steven S ^a   Gleason Guzman, Mary ^b   Gokhale, Vijay ^b   Hurley, Laurence H ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PSOROSPERMIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RETENTION; DRUG SENSITIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHARMACOPHORE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; P-GLYCOPROTEIN; TRANSCRIPTION, GENETIC; XANTHONES;

EID: 56249091092     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0519     Document Type: Article

References (28)

1. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005;32:S9-15.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
3. Taylor CW, Dalton WS, Parrish PR, et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 1991;63:923-9.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
5. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30.
6. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev 2006;58:244-58.
7. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 2004;9:91-105.
8. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 2005;206:173-85.
9. Altenberg GA. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr Med Chem Anti-Cancer Agents 2004;4:53-62.
10. Sauna ZE, Kim IW, Ambudkar SV. Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr 2007;39:481-7.
11. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev 2005;25:453-72.
12. Kupchan SM, Streelman DR, Sneden AT. Psorospermin, a new antileukemic xanthone from Psorospermum febrifugum. J Nat Prod 1980;43:296-301.
13. Cassady JM, Baird WM, Chang CJ. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod 1990;53:23-41.
14. Schwaebe, MK, Moran TJ, Whitten JP. Total synthesis of psorospermin. Tetrahedron Lett 2005;46:827-9.
15. Permana PA, Ho DK, Cassady JM, Snapka RM. Mechanism of action of the antileukemic xanthone psorospermin: DNA strand breaks, abasic sites, and protein-DNA cross-links. Cancer Res 1994;54:3191-5.
16. Fellows IM, Schwaebe M, Dexheimer TS, et al. Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity. Mol Cancer Ther 2005;4:1729-39.
17. Hansen H, Lee S-J, Cassady JM, Hurley LH. Molecular details of the structure of a psorospermin - DNA covalent/intercalation complex and associated DNA sequence selectivity. J Am Chem Soc 1996;118:5553-61.
18. Kwok Y, Zeng Q, Hurley LH. Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites. Proc Natl Acad Sci U S A 1998;95:13531-6.
19. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125-30.
20. Aleman C, Annereau JP, Liang XJ, et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 2003;63:3084-91.
21. Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;78:103 44-52.
22. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-9.
23. Muller C, Laurent G, Ling V. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 1995;163:538-44.
24. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998; 251:252-61.
25. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000;12:31-40.
26. Tsuruo T. Acquired vs innate multidrug resistance and the effect of calcium channel blockers. Prog Clin Biol Res 1986;223:203-16.
27. Shen F, Chu S, Bence AK, et al. Quantitation of doxorubicin uptake, efflux and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2007;324:95-102.
28. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989;49:5002-6.